Recombinant vectors operably encoding a CR2-FH fusion protein comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising the recombinant vector, are described. Also provided are methods of using the compositions for treatment eye diseases such as macular degeneration or glaucoma.

The present invention is directed to an antibody composition for oral administration comprising intact blood-derived polyclonal antibodies that bind to a human tumour necrosis factor (TNF), and means for protecting the antibodies during gastrointestinal transit, as well as methods for manufacturing, kits, and therapeutic uses of the same.

A framework fragment derived from a chicken antibody, in which an amino acid at a particular position is replaced by cysteine, a heavy chain variable region or a light chain variable region including the framework fragment, or an antibody including the heavy chain variable region or the light chain variable region does not induce or prevents formation of disulfide bonds between antibody molecules while maintaining activity and reactivity of the antibody. The antibody introduced with cysteine or an antigen-binding fragment thereof easily binds with a conjugation compound such as a chemotherapeutic drug, an enzyme, an aptamer, a toxin, an affinity ligand, or a detection label, thereby being applied to various fields for diagnosis or treatment of diseases.

The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to glucocorticoid-induced TNF receptor (GITR). In particular aspects of the invention, the antibody molecules specifically bind to human GITR and cynomolgus monkey GITR. The anti-GITR antibody molecules of the invention have been developed and optimized using CDR sequences derived from a murine anti-GITR antibody 6C8. Medical uses of the antibody molecules are disclosed.

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substancesa released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus.

The present invention relates to the microbiomes of humans and other animals as biomarkers and therapeutic targets for regulation or altering of a microbiome profile associated with states of disease or disease risk, using additive and subtractive therapies aimed at restoring a microbiome profile associated with health, with reduced manifestations of disease, or with reduced disease risk. In particular, the invention provides methods of subtractive therapy using microorganism-specific avian egg yolk-derived immunoglobulins (IgY) in a fashion that titrates, without necessarily eliminating, populations of microorganisms known to be associated with human gut and extraintestinal diseases.

Compounds inhibitory to Staphylococcus pseudintermedius Sortase A (SrtA) are identified. The compounds inhibit cell wall-associated protein anchoring to the bacterial cell wall, thus potentially reducing bacterial virulence.

The present invention relates to a method for obtaining an antibody from an avian B cell antibody library, comprising the following steps (a) to (d): (a) a step of allowing an avian B cell antibody library to come into contact with an antigen in the presence of a calcineurin inhibitor and avian serum, (b) a step of selecting avian B cells that bind to the antigen in the step (a), (c) a step of culturing the avian B cells selected in the step (b) in the presence of a calcineurin inhibitor and avian serum, and (d) a step of obtaining the avian B cells obtained through the step (c) and/or an antibody expressed by the avian B cells.

The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.